Source : https://pubmed.ncbi.nlm.nih.gov/39136871/
Atherosclerotic cardiovascular disease (ASCVD), a leading cause of mortality and morbidity, is associated with a substantial healthcare and economic burden. Reduction of low-density lipoprotein cholesterol (LDL-C) to guideline-recommended goals is...
Inclisiran, a novel LDL-C lowering therapy, offers biannual HCP-administered in-office dosing via the buy-and-bill model, potentially improving ASCVD management by enhancing adherence, timely care, and cardiovascular outcomes.
Source : https://pubmed.ncbi.nlm.nih.gov/38592091/
Atherosclerotic cardiovascular disease (ASCVD) represents a major global health challenge, significantly contributing to mortality rates. This chronic inflammatory condition affecting blood vessels is intricately linked to hypercholesterolemia, with elevated levels...
Atherosclerotic cardiovascular disease, driven by hypercholesterolemia, benefits from lipid-lowering therapies. Novel agents like PCSK9 inhibitors and bempedoic acid enhance LDL-C management, addressing statin limitations and advancing cardiovascular risk reduction strategies.
Source : https://pubmed.ncbi.nlm.nih.gov/39275243/
Dyslipidemia is a significant risk factor for atherosclerotic cardiovascular disease (ASCVD). During pregnancy, physiological changes elevate cholesterol and triglyceride levels to support fetal development, which can exacerbate pre-existing conditions and...
Dyslipidemia during pregnancy increases ASCVD risk and complications. Management, including dietary adjustments and selective pharmacological interventions, requires a personalized, multidisciplinary approach to balance maternal and fetal health, especially in inherited dyslipidemia.
Source : https://pubmed.ncbi.nlm.nih.gov/38250316/
Adiponectin, an adipose-derived hormone, plays a pivotal role in glucose regulation and lipid metabolism, with a decrease in circulating adiponectin levels being linked to insulin resistance and prediabetes. This review...
This review explores adiponectin's role in glucose regulation, insulin sensitivity, and lipid metabolism, highlighting strategies to boost its levels for managing prediabetes, and addressing challenges in clinical translation.
Source : https://pubmed.ncbi.nlm.nih.gov/38642715/
Alzheimer's and Parkinson's diseases are two of the most frequent neurological diseases. The clinical features of AD are memory decline and cognitive dysfunction, while PD mainly manifests as motor dysfunction...
Dysregulated lipid metabolism exacerbates Alzheimer's and Parkinson's diseases through various mechanisms, with emerging lipid-targeting therapies, like PPAR agonists and ApoE monoclonal antibodies, offering potential for treatment and prevention.
Source : https://pubmed.ncbi.nlm.nih.gov/38742197/
Diabetic kidney disease (DKD), a significant complication associated with diabetes mellitus, presents limited treatment options. The progression of DKD is marked by substantial lipid disturbances, including alterations in triglycerides, cholesterol,...
This research investigates the connection between lipid metabolism disturbances and diabetic kidney disease (DKD), highlighting mechanisms like ferroptosis, lipophagy, and immune modulation, offering new therapeutic pathways for DKD management.
Source : https://pubmed.ncbi.nlm.nih.gov/38183071/
Clinical practice guidelines are needed for the management of dental implants in chronic steroid users.
This case report highlights implant failure in a 20-year-old female with idiopathic nephrotic syndrome, long-term steroid use, and its impact on bone metabolism and osseointegration, emphasizing the need for specific clinical guidelines.
Source : https://pubmed.ncbi.nlm.nih.gov/38620025/
BACKGROUND Close observation, statins, fibrate treatment, and lifestyle changes can safely manage asymptomatic individuals with severe hypertriglyceridemia (HTG) and minimal risk of symptom development. However, the risk of medication-induced liver...
A 43-year-old man with severe asymptomatic hypertriglyceridemia developed acute liver injury from statin-fibrate therapy. Management required insulin, fibrate adjustment, and lifestyle changes, emphasizing the need for careful monitoring and further research.
Source : https://pubmed.ncbi.nlm.nih.gov/38327998/
Two de novo NNR2022 systematic reviews (SRs) as well as 21 qualified SRs (qSRs) were available. A literature search yielded an additional ~70 SRs, meta-analyses and biomarker papers. Diets lower...
Dietary fat type impacts health outcomes, with PUFAs improving lipid profiles, reducing CVD and diabetes risk, and long-chain n-3 PUFAs lowering triglycerides and cancer risks. Trans fats worsen lipid profiles and CVD.
Source : https://pubmed.ncbi.nlm.nih.gov/38794685/
In response to a perceived epidemic of coronary heart disease, Ancel Keys introduced the lipid-heart hypothesis in 1953 which asserted that high intakes of total fat, saturated fat, and cholesterol...
Ancel Keys' 1953 lipid-heart hypothesis linked fat intake to heart disease risk. However, studies failed to validate it, while cancer and metabolic disorders increased, highlighting the limitations of this approach.
This network meta-analysis evaluates the efficacy of GLP-1RAs in type 2 diabetes, finding tirzepatide most effective for glycaemic control, and CagriSema for weight loss, with concerns over gastrointestinal adverse events at high doses.
Source : https://pubmed.ncbi.nlm.nih.gov/38506081/
P/LP variants in LDLR are common. Expanding the use of reproductive carrier screening to include genes associated with FH presents another opportunity to identify people predisposed to cardiovascular disease.
A study on female reproductive carrier screening found that pathogenic LDLR variants, linked to familial hypercholesterolemia, are common, with higher frequency in Asian populations, offering opportunities for early cardiovascular disease identification.
This review highlights key advancements in understanding how lipid metabolism and complement dysregulation contribute to Age-related Macular Degeneration (AMD). Emerging evidence supports a dual-targeted therapeutic approach combining lipid modulators with complement inhibitors to improve patient outcomes.
.png)
Source : https://pubmed.ncbi.nlm.nih.gov/38397362/
Familial hypercholesterolemia is a genetically determined disease characterized by elevated plasma total and LDL cholesterol levels from the very first years of life, leading to early atherosclerosis. Nutritional intervention is...
This review examines nutritional interventions and nutraceuticals for treating dyslipidemia in childhood, focusing on lipid-lowering supplements, their mechanisms, and the benefits and risks in pediatric patients with severe dyslipidemia.
Source : https://pubmed.ncbi.nlm.nih.gov/38363694/
Children with familial hypercholesterolemia benefit from early detection and optimal treatment of their elevated LDL-C levels.
Early detection and optimal lipid-lowering therapy in children with familial hypercholesterolemia reduce the risk of premature atherosclerotic cardiovascular disease, with novel treatments improving outcomes and cost-effectiveness.
Austria's health technology assessment (HTA) practices underutilize economic evaluations despite rising healthcare costs. This commentary proposes broadening methods beyond cost-effectiveness analysis to reflect diverse values and address high-cost technologies. Innovative approaches may enhance HTA relevance in Austria and globally.
Did you know? The World Health Organization (WHO) considers an intervention cost-effective if it costs three times a person’s income per quality-adjusted life year (QALY) gained. In the U.S., with an average income of around $40,000, this means interventions costing less than $120,000 per QALY are deemed cost-effective. Harvard economist David Cutler suggests $100,000 as a reasonable benchmark.
How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?
.png)
How could planning medical interventions based on an increase in quality-adjusted life year (QALY) shape healthcare policy and decision-making around cost-effective treatments?
At the American Heart Association’s centennial conference, Dr. Amit Khera, Director of Preventive Cardiology and Professor at UT Southwestern Medical Center, and Dr. John L. Sapp, Assistant Dean of Clinical Research at Dalhousie University, presented key findings. Topics included Tirzepatide’s impact on HFpEF and obesity, the comparison of left atrial appendage closure versus anticoagulation for atrial fibrillation, intensive blood pressure control in diabetes, and insights from the VANISH2 trial on ventricular tachycardia. These findings provide healthcare professionals with evidence-based strategies to advance cardiovascular care.
